# Bundxcell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bundxcell

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (May 6, 2026)
- Investors on record: 3

## About

Founded in 2025 and based in Shanghai, China, Beifan Ruhai Biotechnology (Shanghai) Co., Ltd., trading under the name Bundxcell, conducts biotechnology research in areas including stem cell technology, gene diagnostics and medical research development for the life sciences sector. It holds licenses for the sale of Class II and III medical devices and conducts research involving biological materials and new materials technology. The company was founded by Dr. Sheng Ding, while Mr. Yi Zhang is the co-founder and CEO. In May 2026, the company closed a series A+ funding led by Oriental Fortune Capital, with participation from Sichuan Venture Capital and Shanghai Healthcare Capital.
The company works with research institutions, healthcare service providers and commercial biotechnology clients to provide stem cell technology development, gene diagnostic research, medical research and technical consulting.
The company’s revenue is generated from its research services and projects fees.
The company will use the series A+ funding in May 2026 to accelerate the preclinical and clinical research of multiple core R&D pipelines of Bundxcell, further solidify its advantages in two major technology platforms: induced pluripotent stem cells (iPSC) and tissue-specific small molecules, and continuously expand its therapeutic potential in a wider range of disease areas.

## Funding rounds

- Series A, May 6, 2026 — Oriental Fortune Capital, Sichuan Venture Capital, Shanghai Healthcare Capital

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A